MRI Fusion Biopsy vs. Micro-Ultrasound Guided Biopsy

Clinicaltrials.gov ID: NCT05471128
db-list-check Status RECRUITING
b-loader Phase
b-people Age 18 - 99 Years
b-bullseye-arrow Enrollments 30

Conditions

Prostate Cancer

Summary

The purpose of this study is to find out how best to detect clinically significant lesions of prostate cancer by using micro-ultrasound technology (ExactVu) and by multiparametric magnetic-resonance imaging (mpMRI).

Detailed Description

This is a pilot clinical trial with 30 patients with either: 1) suspected prostate cancer (based on elevated PSA or abnormal digital rectal exam (DRE), or 2) known low-risk prostate cancer being managed with active surveillance.

Enrolled patients will undergo MRI fusion biopsy and standard-template 12 core TRUS biopsy as the standard-of-care. Patients will also undergo micro-ultrasound evaluation and targeted biopsy if lesions are identified. Detection rates of clinically significant lesions by ExactVu and by MRI will be compared.

Locations

1 location Found with status Recruiting

Status

  • RECRUITING

Contact Person

Principal Investigator

  • Andrew McIntosh, MD

Eligibility Criteria

Inclusion Criteria:

1. Patients scheduled to undergo biopsy and with one of the following:

* Men with suspicion of prostate cancer
* Men on active surveillance
2. Age ≥18 [30]
3. Have available multiparametric prostate MRI
4. Able to provide written, informed consent
5. No significant medical illness which in the opinion of the Investigator would preclude entry to study procedures
6. Be willing and able to comply with scheduled visits

Exclusion Criteria:

1. Previously confirmed prostate cancer diagnosis with Grade Group >= 2
2. Unable to undergo prostate biopsy
3. Prostate MRI unable to be evaluated using the PI-RADS v2 criteria
4. Men with contraindication for MRI or a prostate biopsy
5. Prostate biopsy within 8 weeks prior to mpMRI.
6. Any history of prostate treatment

Outcome Measures

Primary Outcome Measures

Detection Rate

Time Frame: 2 years

Feasibility of ExactVu

Time Frame: 2 years

Secondary Outcome Measures

Predictive Performance Measures

Time Frame: 2 years

Predictive Performance Measures

Time Frame: 2 years

Timeline

  • Last Updated
    February 15, 2024
  • Start Date
    July 22, 2022
  • Today
    January 16, 2025
  • Completion Date ( Estimated )
    June 1, 2025

Similar Trials

light-list-check RECRUITING light-blue-people 21 - 64 Years
light-list-check RECRUITING light-blue-people ≥ 18 Years
light-list-check RECRUITING light-blue-people ≥ 65 Years